The Quiet Consolidation Reshaping Cancer Care
Across mid-sized American cities and rural corridors, oncology practices that have operated independently for decades are signing acquisition deals with hospital systems – and most patients have no idea the ownership has changed. The transactions rarely make local news. No press conferences, no announcements in waiting rooms. A practice that a community trusted for thirty years simply becomes a hospital department, billing under a new tax ID, with the same doctors in the same building wearing the same white coats.
What looks like business as usual on the surface is actually a structural shift in how cancer care gets delivered, priced, and controlled in America. Independent oncology has been under financial pressure for years, and hospital networks have taken full advantage. The consolidation is accelerating, and its consequences – for patients, for physicians, and for the cost of treatment – are only beginning to surface.
Why Independent Oncology Practices Are Selling
Running an independent oncology practice has always required managing extraordinary complexity. Oncologists are among the highest-volume drug purchasers in medicine, buying and administering chemotherapy directly through a federal program called 340B that allows certain providers to purchase drugs at a discount. For independent practices, that drug margin has historically been a financial lifeline, offsetting the administrative costs of running a small business while keeping physician salaries competitive. But that margin has been under pressure for years. Pharmacy benefit managers have renegotiated reimbursement rates, and payers have pushed back on drug administration fees, squeezing the independent model from multiple directions at once.
The staffing and regulatory burden compounds the financial strain. Independent oncology practices must maintain prior authorization teams, compliance officers, billing specialists, and oncology-certified nurses – all without the administrative infrastructure of a large institution. When a hospital network offers an acquisition, it often comes with a guarantee: the practice’s overhead disappears into the system’s shared services, physician compensation gets locked in for several years, and the doctors stop worrying about accounts receivable. For a physician in their late fifties who has spent decades building a practice, that offer is hard to decline.
What Hospital Ownership Actually Changes
The most immediate and measurable change after a hospital acquires an oncology practice is the price of care. Hospital outpatient departments operate under a different reimbursement structure than physician offices. Medicare pays them more for the same infusion services, the same drugs, and the same office visits. The logic behind this gap – called the “site-of-care differential” – was originally designed to compensate hospitals for maintaining emergency capacity and treating complex cases. In practice, it means that a chemotherapy infusion administered in what used to be an independent clinic can cost a patient and their insurer significantly more the day after acquisition, without any change in the actual treatment.
Commercial insurers, not just Medicare, follow similar patterns. Once a practice becomes a hospital outpatient department, the hospital’s master contract with insurers typically governs billing, and those rates are almost universally higher than what the independent practice negotiated on its own. Patients with high-deductible plans often absorb part of that increase directly. A cancer patient who budgeted carefully for treatment costs under an independent practice can find themselves facing a very different financial picture within months of a sale closing.
Beyond pricing, hospital ownership changes how oncologists practice medicine. In an independent setting, physicians have direct control over which drugs they stock, which clinical trials they participate in, and how they structure treatment protocols. Inside a hospital system, those decisions migrate to pharmacy and therapeutics committees, administrative formularies, and system-wide protocols that may or may not align with what an individual oncologist would choose. The physician still sees the patient, still makes the diagnosis, still orders the treatment – but the institutional layer between the doctor and the decision grows considerably thicker.
Patient experience often changes in ways that are harder to quantify but no less real. Independent oncology practices are frequently known for tight scheduling, consistent care teams, and direct access to a physician by phone. Hospital systems operate at scale, which brings longer wait times, more handoffs between staff, and a navigation experience built for volume rather than continuity. For cancer patients managing complex treatment schedules while often feeling their worst, those logistical frictions carry real weight.
The Geography of the Consolidation
The acquisitions are not evenly distributed. Rural and semi-rural markets have seen the fastest consolidation, largely because hospital systems recognize that oncology is one of the few high-revenue service lines they can expand without building new facilities. Acquiring a regional practice instantly adds cancer care capacity, a loyal patient base, and a referral network. In markets where the hospital may already be the dominant employer and the largest insurer contractor, adding oncology control reinforces that position considerably. Patients in these communities often have no alternative – the next independent oncology group may be an hour away, if one exists at all.
Mid-sized metro markets tell a different story, where multiple hospital systems are actively competing to acquire the same practices. In some of these markets, independent oncology groups have found themselves fielding competing acquisition offers from two or three systems simultaneously, which has briefly created some negotiating leverage for physicians. That window may be closing. As major systems finalize their rosters of acquired practices, the number of independent groups available to acquire drops, and the urgency for remaining independents to find a buyer before consolidation locks them out of referral networks intensifies.
Physicians Caught in the Middle
For oncologists themselves, the acquisition calculus is genuinely complicated. Many entered medicine with the intention of running their own practice, making their own clinical and business decisions. That independence has real value to them, and relinquishing it is not a decision most make lightly. But the alternative – staying independent in a market where hospital systems control referrals, insurers favor facility-based billing, and administrative costs keep climbing – can feel increasingly untenable.
Employment contracts in hospital acquisitions typically include compensation guarantees ranging from three to five years, after which the physician’s pay reverts to a productivity-based formula determined by the institution. Those post-guarantee years are where physician dissatisfaction tends to spike. Oncologists who sold their practices expecting to maintain their income and autonomy often find that the hospital’s definition of productivity does not match what they built their practice around. Burnout rates among hospital-employed oncologists are notably higher than among independent physicians, a dynamic that matters enormously in a field where patient relationships form over years of difficult treatment.
Some oncologists are exploring alternatives that fall between full independence and full hospital employment. Management services organizations, or MSOs, offer back-office infrastructure and contracting support while leaving clinical and financial control with the physician group. Private equity-backed oncology networks have also entered the market, offering capital and scale without hospital ownership. Whether those models offer meaningful protection from the same pressures that drove the hospital consolidation trend is a question that independent oncologists are actively working out – often with no clear answer yet in sight.
What Comes Next for Patients
Policymakers have taken notice of the site-of-care pricing disparity, and several proposals circulating in Congress would equalize Medicare reimbursement between hospital outpatient departments and physician offices for certain services. If enacted, that change would significantly reduce the financial incentive for hospital systems to acquire oncology practices in the first place. But equalizing reimbursement would also reduce the revenue hospitals receive from practices they have already acquired, which has generated strong opposition from hospital industry groups who argue that cutting outpatient rates threatens their ability to cross-subsidize money-losing services like emergency care and rural access.
Patients navigating this landscape have limited tools. Most do not know whether their oncology practice has been acquired by a hospital system, have no easy way to compare what their treatment will cost under different ownership structures, and rarely have the bandwidth during active cancer treatment to investigate billing arrangements. The information gap between what the healthcare industry knows about consolidation and what patients understand about its effects on their care is wide, and no part of the system is currently designed to close it.
What is clear is that the independent oncology practice – a model that gave physicians control and gave patients consistent, personal relationships during some of the hardest years of their lives – is becoming rarer with each quarter. The doctors who built those practices are retiring or selling, and the institutional infrastructure replacing them is not designed around the same values. Whether hospital-owned cancer care delivers equivalent outcomes at higher cost, or whether the scale eventually produces genuine improvements in care coordination, is a question that will take years of data to answer. In the meantime, the sales keep closing, quietly, in cities and towns across the country.
